Sisram Medical reported H1 2026 results showing strong revenue growth in Asia-Pacific markets, offsetting margin compression from manufacturing and supply-chain costs. The company's diversified geographic footprint and energy-device portfolio—spanning RF microneedling, ultrasound, and laser platforms—continue to drive adoption across emerging markets.
Business & M&A
Sisram Medical H1 2026: APAC Growth Offsets Margin Pressure
Sisram delivered solid interim results driven by Asia-Pacific strength, though gross margins faced headwinds.
Sisram's APAC growth offset gross margin headwinds in H1 2026.
For practices in APAC regions, Sisram's growth signals rising demand for premium energy devices and the company's commitment to regional support. Margin pressure is a sector-wide issue tied to component costs and competitive pricing; Sisram's ability to grow volumes while managing profitability matters for device acquisition decisions and lease-vs.-buy economics. Practices should monitor whether Sisram's pricing strategies remain favorable as the company navigates cost inflation.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.